Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study-Reference-Cited by-同舟云学术

Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

Published:2020-01-16 Issue:4 Volume:95 Page:362-371
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Dreyling Martin¹,Santoro Armando²,Mollica Luigina³,Leppä Sirpa⁴,Follows George⁵,Lenz Georg⁶,Kim Won Seog⁷,Nagler Arnon⁸,Dimou Maria⁹,Demeter Judit¹⁰,Özcan Muhit¹¹,Kosinova Marina¹²,Bouabdallah Krimo¹³,Morschhauser Franck¹⁴,Stevens Don A.¹⁵,Trevarthen David¹⁶,Munoz Javier¹⁷,Rodrigues Liana¹⁸,Hiemeyer Florian¹⁹,Miriyala Ashok²⁰,Garcia‐Vargas Jose²⁰,Childs Barrett H.²⁰,Zinzani Pier Luigi²¹^ORCID

Affiliation:

1. Department of Medicine III University Hospital, LMU Munich Germany

2. Humanitas Clinical and Research Center Rozzano Italy

3. Maisonneuve‐Rosemont Hospital Research Centre Montréal Canada

4. Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki Helsinki Finland

5. Cambridge University Hospitals NHS Foundation Trust Cambridge UK

6. Translational Oncology University Hospital Münster Münster Germany

7. Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea

8. Chaim Sheba Medical Center Tel Aviv University, Tel HaShomer Tel Aviv‐Yafo Israel

9. School of Medicine National and Kapodistrian University of Athens Athens Greece

10. First Department of Internal Medicine, Semmelweis University Budapest Hungary

11. Department of Internal Medicine, Division of Hematology, Ankara University Ankara Turkey

12. Kemerovo Regional Clinical Hospital Kemerovo Russian Federation

13. Department of Hematology, University Hospital of Bordeaux, Hôpital Haut‐Lévêque Pessac France

14. Univ. Lille, CHU Lille, EA 7365 ‐ GRITA ‐ Groupe de Recherche sur les formes Injectables et les Technologies Associées Lille France

15. Norton Cancer Institute Louisville Kentucky

16. Comprehensive Cancer Care and Research Institute of Colorado, LLC Englewood Colorado

17. Banner MD Anderson Cancer Center Clinic Gilbert Arizona

18. Bayer SA São Paulo Brazil

19. Pharmaceutical Division Bayer AG Berlin Germany

20. Bayer HealthCare Pharmaceuticals, Inc. Whippany New Jersey

21. Institute of Hematology “Seràgnoli”, University of Bologna Bologna Italy

Funder

Bayer

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25711

Reference30 articles.

1. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

3. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL

4. A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

5. PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis;Recent Patents on Anti-Cancer Drug Discovery;2024-02

2. Beta-blocker adjunct therapy as a prospective anti-metastatic with cardio-oncologic regulation;Clinical & Experimental Metastasis;2024-01-05

3. Targeted therapies for follicular lymphoma;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

4. Outcomes of COVID‐19 in patients with lymphomas participating in registered clinical trials: A real‐world study from China in the Omicron outbreak era;Cancer Medicine;2023-11-27

5. Management and clinical outcomes of follicular lymphoma across continuous lines of treatments: a retrospective analysis in China;Frontiers in Oncology;2023-10-24